<scp>SARS‐CoV</scp>‐2 infection in beta thalassemia: Preliminary data from the Italian experience
Irene Motta, Margherita Migone De Amicis, Valeria Maria Pinto, Manuela Balocco, Filomena Longo, F Bonetti, Barbara Gianesin, Giovanna Graziadei, Maria Domenica Cappellini, Lucia De Franceschi, Antonio Piga, Gian Luca Forni
Abstract
again formulated (FVIII <1%, inhibitor titer 19 BU) and the patient was treated with the same anti-hemorrhagic and immunosuppressive treatment, reaching CR on day +20. In addition, the patient received anti-viral drugs (lopinavir-ritonavir 400 mg/twice daily) and noninvasive mechanical ventilation with oxygen as treatment for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) infection, leading to the resolution of the disease on day +14.
Topics & Concepts
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)ThalassemiaCoronavirus disease 2019 (COVID-19)Beta thalassemia2019-20 coronavirus outbreakMedicineVirologyInternal medicineInfectious disease (medical specialty)DiseaseOutbreakHemoglobinopathies and Related DisordersIron Metabolism and DisordersParvovirus B19 Infection Studies